

SPRING GROUP MEETING

# Seattle

# Lung Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

# Lung Committee

## Leadership

Chair: ..... Jhanelle E. Gray, MD  
 Vice-Chair: ..... Roy S. Herbst, MD, PhD  
 Executive Officer: ..... Anne Chiang, MD, PhD  
 Statisticians: ..... Mary Redman, PhD  
 ..... Michael Wu, PhD  
 ..... Yingqi Zhao, PhD  
 ..... Kari Chansky, MS  
 ..... Mia Hsieh, MS  
 ..... Katie Minichiello, MS  
 ..... Jieling Miao, MS  
 ..... James Moon, MS

## Scientific Leadership

Translational Medicine:  
 Biology/Pathology: ..... Philip C. Mack, PhD  
 ..... Fred R. Hirsch, MD, PhD  
 ..... Ignacio I. Wistuba MD  
 Imaging: ..... Chadwick L. Wright MD, PhD  
 ..... Myrna C. Godoy, MD, PhD  
 Radiation Oncology: ..... Henry Park, MD  
 Surgery: ..... Wayne L. Hofstetter, MD  
 Subcommittee Chairs:  
 Early Stage Disease: ..... Wayne L. Hofstetter, MD  
 ..... Raymond Osarogiagbon, MD  
 Locally Advanced Disease: ..... Shirish Gadgeel, MD (Early Therapeutics)  
 Metastatic Disease: ..... Ross Camidge, MD  
 ..... Karen Reckamp, MD  
 Community Engagement: ..... Paul J. Hesketh, MD  
 ..... Suzanne Cole, MD

## Designates

Cancer Control Liaison: ..... Gary E. Goodman, MD  
 DEI Champion: ..... Lucy Gansauer, MSN, RN, OCN, CCRP  
 Veterans Affairs: ..... Chao H. Huang, MD  
 ..... Cheryl M. Czerlanis, MD  
 Data Coordinators: ..... Amy Johnson, CCRP  
 ..... Kevin Moralda, BS  
 ..... Larry Kaye  
 ..... Louise Highleyman, BA  
 ..... Pasarlai Ahmadzai, MD, MPH  
 Clinical Research Project Manager: ..... TBD  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Rosalie Zablocki, RN  
 ..... Lisa G. Davis, RN

Patient Advocate: ..... Judy Johnson, MBA  
 Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Safae Ghouraihi, PharmD  
 Protocol Project Managers: ..... Justine Trevino  
 ..... Jennifer Beeler (Lung-MAP)  
 Clinical Trials Program Manager: ..... Mariah Norman, MS

## Time/Location

Friday, April 5, 2024 8:30 a.m. - 11:30 a.m.  
 Room: Quinault (Level 5)

## Agenda

**8:30 - 8:35 am**      **General Update:** Jhanelle E. Gray, MD

**8:35 - 8:40 am**      **Patient Advocate Update:** Judy Johnson, MBA

**8:40 - 8:45 am**      **Thoracic Surgery Session:** Eric Toloza, MD, PhD

**8:45 - 8:50 am**      **Thoracic Radiation Session:** Megan Daly, MD

**8:50 - 8:55 am**      **Translational Medicine Session:** Philip C. Mack, PhD

**8:55 - 9:00 am**      **Community Engagement Core:** Paul J. Hesketh, MD

**9:00 - 9:05 am**      **DEI Session:** Lucy Gansauer, MSN, RN

**9:05 - 9:13 am**      **Encore Presentation of the ASCO S1929 Trial -**  
 Nagla Abdul Karim, MD, PhD, Professor of Medicine, University of  
 Virginia, and Director of Phase I Trials, Inova Schar Cancer Center

**9:13 - 9:21 am**      **Evolution of Biomarkers for SCLC and New Study**  
**Concept -** Triparna Sen, PhD, Associate Professor of Oncological  
 Sciences, and Co-Director, Lung Cancer PDX Program, Icahn School of  
 Medicine at Mount Sinai

**9:21 - 9:26 am**      **S2409 PRISM Trial -** Anne Chiang, MD, Associate  
 Professor of Medicine and Associate Cancer Center Director, Clinical  
 Initiatives, Yale School of Medicine

**9:26 - 9:46 am**      **Small Cell Lung Cancer: New Frontiers Panel Q&A**

Moderator: Jhanelle E. Gray, MD

Panelists: Nagla Abdul Karim, MD, PhD  
 Sonam Puri, MD  
 Triparna Sen, PhD  
 Anne Chiang, MD  
 Shakun Malik, MD  
 David MacPherson, PhD



# Lung Committee

## 9:46 - 10:18 am Thoracic Medical Oncology: Jhanelle Gray, MD

S2302, "Project Pragmatica-Lung Trial." Dr. Karen Reckamp. Activated: 3/6/23; Accrual Goal: 700; Accrual: 345

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Drs. Karen Reckamp and David Gandara (SWOG). Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3303.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB- STUDY)." Dr. Karen Reckamp (SWOG), Dr. Suki Padda and Dr. David Gerber (ECOG). Activated: 4/2/21; Accrual Goal: 116; Accrual: 228.

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)". Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG). Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 16.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small- Cell Lung Cancer (MAVERICK)." Dr. Chad Rusthoven (SWOG). Activated: 1/10/20; Accrual Goal: 668; Accrual: 202.

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Dr. Raid Aljumaily (SWOG). Activated: 6/15/20; Accrual Goal: 47; Accrual: 35.

S1914, "A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC." Dr. Megan Daly (SWOG). Activated: 3/25/20; Accrual Goal: 480; Accrual: 322.

EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non- Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Anne Chiang (SWOG). Activated: 2/28/19; Accrual Goal: 600; Accrual: 558 total: 83.

## 10:18 - 11:30 am Open Discussion

## Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21.

S1900G, "A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2302, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev. Activation: 3/6/23.

# Lung Committee

**CTSU/EA5163/S1709**, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

**CTSU/A081801**, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

**CTSU/A151216**, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

**CTSU/E4512**, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

**CTSU/EA5181**, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20.

**CTSU/EA5182**, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated:10/22/20.

**CTSU/EA5191**, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20.

**CTSU/NRG-LU002**, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

**CTSU/NRG-LU005**, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

**CTSU/NRG-LU007**, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

## Closed Studies

**CTSU/NRG-CC003**, "Randomized Phase II/III Trial of Prophylactic Cranial

Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

**S1800A**, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

**S1800D**, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

**S1900A**, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

**S1900B**, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

**S1900C**, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

**S1900E**, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

**S1929**, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

**S1934**, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of

# Lung Committee

Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

## NCI-Approved Concepts

**S1900J**, "A Phase II Study of Amivantamab-vmjw in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel.

**S1800E**, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

**S2313**, "Neoadjuvant chemo-durvalumab for clinical stage I, 2-3.9cm, non-small cell lung cancer: a randomized controlled trial." Drs. Gibney and Wrangle.

**S2404**, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

## Concepts in Development

**S1900M**, "A Randomized Phase II Study of Trastuzumab Deruxtecan (T-DXd) in Participants with HER2 Wild-Type, HER2 (ERBB2) Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Saltos and Doroshow.

**S2409**, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang and Chiappori.

**S2410**, "A randomized phase II study of a PDL1 inhibitor and iadademstat (ORY-1001) versus investigator's choice of standard of care for second line treatment of extensive stage small cell lung cancer (SCLC)." Drs. Santana-Davila and Puri.

**S2414**, "Incorporating Pathologic Response in Patients with Early Stage Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon.

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall

2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

## Published/Accepted Manuscripts

**LUNGMAP** Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke C, LeBlanc M, Kelly K, Gray J, Redman M. *JCO Precision Oncology* Sep;7:e2300218, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37677122/>

**LUNGMAP** Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships. Herbst RS, Blanke CD, Sigal E. *Clinical Cancer Research* Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37903180/>

**S1400I** Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial. *Clinical Cancer*. Parra E, Duose D, Zhang J, Redman M, Lazzano Segura R, Marques-Puibelli M, Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Al-atrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C, Manyam G, Zhang J, Song X, Rojas F, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Van Nostrand D, Provencher J, Yu J, Cerami E, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Biswas R, Kim-Schulze S, Kelly K, Gnjatich S. *Clinical Cancer Research* Jan 26. doi: 10.1158/1078-0432.CCR-23-0251. Online ahead of print., 2024.

<https://pubmed.ncbi.nlm.nih.gov/38277235/>

## Submitted Manuscripts

**S0819** External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted, 2023.

**S1400** Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch FR, Mack P, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman M. Submitted, 2024.

## Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929	S1933	S2302	A081801
Ascension Providence Hospitals - Southfield	13	-	-	-	-	-	-	3	-	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	1	-	-	-	-	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	2	-
Baptist Mem Health Care/Mid South MU-NCORP	35	-	-	2	1	-	7	2	-	7	4
Baylor College of Medicine/Duncan CCC	-	-	-	2	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	5	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	2	-	-	-	-	2	10
Ca Res Consort of W Mich NCORPP	3	-	-	-	-	-	4	-	-	1	-
Cancer Research for the Ozarks NCORP	34	-	3	-	-	-	4	2	3	3	-
Ca Res of Wisconsin and N Mich Consort	27	-	2	-	4	-	4	-	-	-	-
Carle Cancer Center NCORP	3	1	-	1	1	-	6	-	-	4	-
Cedars-Sinai Medical Center	17	-	-	-	1	-	1	-	-	6	-
City of Hope Comprehensive Cancer Center	5	1	-	1	-	-	-	-	-	2	-
Columbia U MU NCORP	11	-	-	-	-	-	-	-	-	2	-
Columbus NCORP	28	-	-	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	39	-	-	-	-	-	1	1	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	2	-	-	-	-	-	-	2	-	-	1
Essentia Hlth NCORP	16	-	2	-	-	-	3	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-	-	-	-
Froedtert & the Med College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	-	1	-	-	2	3	1	-	-
Georgia NCORP	59	-	4	3	1	-	7	-	-	6	-
Gulf South Minority Underserved NCORP	22	-	1	1	-	-	3	1	-	4	1
Hawaii Minority Underserved NCORP	27	-	-	1	-	-	-	-	-	1	-
Heartland Cancer Research NCORP	145	-	9	5	5	-	32	19	4	26	-
Henry Ford Hospital	7	-	-	-	-	-	-	1	-	-	2
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	2	-	-	-	-	-	-	-
Kaiser Permanente NCORP	86	-	6	-	8	-	2	-	-	13	3
Lahey Hospital and Medical Center	32	-	-	-	-	-	4	1	2	9	-
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	23	-	1	-	-	-	-	2	-	2	-
Massachusetts Veterans ERIC	62	-	3	3	1	-	-	-	-	2	10
Med U South Carolina MU NCORP	17	-	1	-	1	1	-	-	-	6	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	1	-	-	-
Michigan Cancer Research Consortium NCORP	107	-	4	2	7	1	9	3	-	7	-
Mission Hospital	1	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	16	2	1	1	1	1	-	-	-	17	17
Montana Cancer Consortium NCORP	25	-	-	-	1	-	-	3	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	9	1	-	1	-
NCORP of the Carolinas (Prisma Health NCORP)	19	-	-	-	1	-	-	-	-	-	-

## Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929	S1933	S2302	A081801
National Cancer Center-Korea	-	-	-	1	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	1	-	-	-
New Mexico Minority Underserved NCORP	83	-	-	1	2	-	6	5	1	1	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-	1
Northwestern University LAPS	26	1	2	1	-	-	-	4	-	8	-
Oregon Health and Science University	9	-	1	-	-	-	1	-	-	-	7
Pacific Cancer Research Consortium NCORP	17	-	-	-	-	-	-	3	-	-	-
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	1	-	-	-	1
Salem Hospital	4	-	-	-	1	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	51	-	1	7	1	-	9	8	-	1	-
Sutter Cancer Research Consortium	29	-	-	-	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	11	-	2	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	37	3	6	1	-	1	11	2	-	5	-
UC Irvine Hlth/Chao Family CCC	26	-	-	1	-	-	4	-	-	1	-
UC San Diego Moores Cancer Center	14	-	-	-	1	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	66	-	5	8	6	-	-	3	3	9	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	5	-	-	5	-	-	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	-	-	8	-
University of Arkansas for Medical Sciences	11	-	1	-	-	-	11	-	-	2	-
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	13	-	-	4	-	-	4	2	-	2	2
U Kansas CC - MCA Rural MU NCORP	93	-	1	1	1	-	-	-	-	1	1
University of Kentucky/Markey Cancer Center	50	-	-	1	-	-	-	-	-	3	-
U Michigan Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	-	2	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	33	-	-	1	-	-	3	2	11	2	-
University of Rochester LAPS	65	-	2	-	6	-	3	-	-	8	-
U Texas HSC at San Antonio	-	-	-	-	-	-	-	1	-	6	-
U Texas MD Anderson CC LAPS	3	6	-	3	-	-	1	4	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	3	-	-	3	1	-	1	-
Upstate Carolina NCORP	38	-	-	-	-	-	2	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	1	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	40	-	-	1	1	-	9	-	-	2	-
Yale University - Yale Cancer Center LAPS	25	-	-	4	3	1	8	-	-	10	6
ALLIANCE	790	3	15	16	21	2	30	9	5	31	-
CCTG	-	-	-	23	-	-	-	-	-	-	-
ECOG-ACRIN	349	3	5	7	18	-	23	10	-	15	-
NRG	427	1	4	61	12	1	68	6	1	15	-
<b>Total</b>	<b>3,249</b>	<b>21</b>	<b>82</b>	<b>185</b>	<b>109</b>	<b>8</b>	<b>300</b>	<b>106</b>	<b>32</b>	<b>257</b>	<b>67</b>



## Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	A171901	E4512	E45162	E45163	E45181	E45182	E45191	NRGLU002	NRGLU005
Ascension Providence Hospitals - Southfield	-	15	-	1	1	2	3	-	1	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	-	-	-	-	2
Banner University Medical Center - Tucson	-	7	-	2	-	-	10	-	-	-	1
Baptist Mem Health Care/Mid South MU-NCORP	-	26	-	-	-	1	1	2	-	1	4
Baylor College of Medicine/Duncan CCC	-	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	3	-	-	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	54	-	-	-	17	21	1	4	-	-
Ca Res Consort of W Mich NCORPP	-	1	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	5	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	1	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	2	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	3	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	8	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-	-	-	-	4	-	-	-	-
Froedtert & the Med College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	9	-	-	-	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	-	3	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	29	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	8	-	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	203	-	5	-	8	-	4	-	-	-
Lahey Hospital and Medical Center	-	30	-	-	-	2	-	-	-	-	-
Loma Linda University Medical Center	-	10	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	24	-	-	-	2	2	-	-	-	-
Massachusetts Veterans ERIC	-	31	-	-	-	3	-	-	2	-	-
Med U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	83	-	1	-	5	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1	1	-	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	1	-	-	-	-	-	-	-	-	-



## Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	A171901	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	NRGLU002	NRGLU005
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	23	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	4	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	3	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	11	-	-	-	-	3	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	5	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	44	-	1	-	6	-	1	-	-	-
UC Irvine Hlth/Chao Family CCC	-	15	-	1	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	5	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	3	-	1	-	1	3	-	-	-	1
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	24	-	1	-	2	-	1	-	-	-
University of Colorado Cancer Center LAPS	-	58	-	2	-	-	-	-	1	-	1
U Kansas CC - MCA Rural MU NCORP	-	31	-	-	-	7	-	-	3	-	2
University of Kentucky/Markey Cancer Center	-	5	-	-	-	-	-	-	-	-	-
U Michigan Comprehensive Cancer Center LAPS	-	62	-	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	26	-	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	1	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	4	19	-	-	-	1
U Texas HSC at San Antonio	-	-	-	-	-	2	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	2	-	1	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	-	-	1	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	1	-	-	-	-	-	-	-	1	-
Western States Cancer Research NCORP	-	1	-	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	2	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	56	-	4	-	13	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>3</b>	<b>966</b>	<b>1</b>	<b>20</b>	<b>1</b>	<b>81</b>	<b>72</b>	<b>10</b>	<b>11</b>	<b>2</b>	<b>13</b>

## Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	NRGLU006	R1308
Ascension Providence Hospitals - Southfield	-	-
Ascension Via Christi Hospitals Wichita	-	-
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	-
Baylor College of Medicine/Duncan CCC	3	-
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Ca Res Consort of W Mich NCORPP	-	-
Cancer Research for the Ozarks NCORP	-	-
Ca Res of Wisconsin and N Mich Consort	-	-
Carle Cancer Center NCORP	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
Columbia U MU NCORP	-	-
Columbus NCORP	-	-
CommonSpirit Health Research Institute	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-
Dayton NCORP	-	-
Essentia Hlth NCORP	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-
Froedtert & the Med College of Wisconsin LAPS	-	-
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCORP	-	-
Gulf South Minority Underserved NCORP	-	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Kaiser Permanente NCORP	-	-
Lahey Hospital and Medical Center	-	-
Loma Linda University Medical Center	-	1
Loyola University Medical Center	-	-
Massachusetts Veterans ERIC	-	-
Med U South Carolina MU NCORP	-	-
Mercy Medical Center - Des Moines	-	-
Michigan Cancer Research Consortium NCORP	-	-
Mission Hospital	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-

	NRGLU006	R1308
National Cancer Center-Korea	-	-
Nevada Cancer Research Foundation NCORP	-	-
New Mexico Minority Underserved NCORP	-	-
Northwell Health NCORP	-	-
Northwestern University LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-
SCL Health Saint Joseph Hospital	-	-
Salem Hospital	-	-
Southeast Clin Onc Res Consort NCORP	-	-
Sutter Cancer Research Consortium	-	-
The Don and Sybil Harrington Cancer Center	-	-
James Graham Brown CC at U Louisville	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-
UC Irvine Hlth/Chao Family CCC	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-
University of Arkansas for Medical Sciences	-	-
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	-
University of Colorado Cancer Center LAPS	-	-
U Kansas CC - MCA Rural MU NCORP	-	-
University of Kentucky/Markey Cancer Center	-	-
U Michigan Comprehensive Cancer Center LAPS	-	-
University of Mississippi Medical Center	-	-
U of Oklahoma Health Sciences Center LAPS	-	-
University of Rochester LAPS	-	-
U Texas HSC at San Antonio	-	-
U Texas MD Anderson CC LAPS	-	-
U Utah - Huntsman Ca Inst LAPS	-	-
Upstate Carolina NCORP	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-
Western States Cancer Research NCORP	-	-
William Beaumont Hospital-Royal Oak	-	-
Wisconsin NCORP	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
CCTG	-	-
ECOG-ACRIN	-	-
NRG	-	-
<b>Total</b>	<b>3</b>	<b>1</b>

